Cilostazol
What is Cilostazol?
Cilostazol is a medication used to improve symptoms of intermittent claudication (pain in the legs when walking due to narrowed arteries). It works by widening blood vessels and decreasing the clotting ability of platelets in the blood.
Cilostazol Product Specifications
- Active Ingredient: Cilostazol
- Dosage Forms: Tablets (50mg and 100mg)
- Indications: Treatment of intermittent claudication
- Mechanism of Action: Phosphodiesterase III inhibitor
- Half-life: 11-13 hours
- Protein Binding: 95-98%
- Metabolism: Hepatic
- Excretion: Urine (74%), Feces (20%)
Cilostazol Dosage Information
| Patient Group | Recommended Dosage | Special Considerations |
|---|---|---|
| Adults | 100mg twice daily | Take 30 minutes before or 2 hours after breakfast and dinner |
| Elderly | 50mg twice daily initially | May increase to 100mg twice daily if tolerated |
| Renal Impairment | No dosage adjustment needed | Monitor for adverse effects |
| Hepatic Impairment | 50mg twice daily | Use with caution in severe impairment |
FAQs About Cilostazol
How long does it take for Cilostazol to work?
Patients may begin to notice improvement in walking distance within 2-4 weeks of starting Cilostazol treatment. However, the full therapeutic effect may take up to 12 weeks of continuous use. Clinical studies have shown that the maximum benefit typically occurs after 3 months of treatment. It's important to continue taking the medication as prescribed even if immediate results aren't apparent.
Can Cilostazol be taken with food?
Cilostazol should be taken on an empty stomach, either 30 minutes before or 2 hours after meals. Food, especially high-fat meals, can significantly increase the absorption of Cilostazol, potentially leading to higher than desired blood levels of the medication. This increased absorption may raise the risk of side effects without providing additional therapeutic benefits.
What are the common side effects of Cilostazol?
The most frequently reported side effects of Cilostazol include headache (27-34% of patients), diarrhea (12-19%), abnormal stools (12-15%), dizziness (9-10%), and palpitations (5-10%). These side effects are typically mild to moderate in severity and often diminish with continued treatment. If side effects persist or become bothersome, patients should consult their healthcare provider about potential dosage adjustments.
Cilostazol Clinical Benefits
Clinical trials have demonstrated that Cilostazol significantly improves walking distance in patients with intermittent claudication:
- Increases maximal walking distance by approximately 50% compared to placebo
- Improves pain-free walking distance by 35-50%
- Enhances quality of life measures in claudication patients
- May reduce progression of atherosclerosis
Cilostazol Drug Interactions
| Interacting Drug Class | Potential Interaction | Management Recommendation |
|---|---|---|
| Strong CYP3A4 Inhibitors | Increased Cilostazol levels | Reduce Cilostazol dose to 50mg twice daily |
| Strong CYP2C19 Inhibitors | Increased Cilostazol levels | Consider dose reduction |
| Antiplatelets/Anticoagulants | Increased bleeding risk | Monitor for bleeding |
| Grapefruit Juice | Increased absorption | Avoid concurrent use |
Additional Cilostazol FAQs
Can Cilostazol be used in patients with heart failure?
Cilostazol is contraindicated in patients with heart failure of any severity class. As a phosphodiesterase III inhibitor, Cilostazol may increase the risk of mortality in patients with congestive heart failure. Alternative treatments should be considered for intermittent claudication in this patient population. Healthcare providers should carefully assess cardiac status before initiating Cilostazol therapy.
Is Cilostazol safe for long-term use?
Cilostazol has been shown to be safe for long-term administration in clinical studies lasting up to 6 months. The benefits of continued therapy should be periodically reassessed, as some patients may experience diminishing returns over time. Regular follow-up with a healthcare provider is recommended to monitor both efficacy and safety during prolonged treatment with Cilostazol.
How does Cilostazol compare to other claudication treatments?
Cilostazol has demonstrated superior efficacy to pentoxifylline in head-to-head clinical trials, with significantly greater improvements in walking distance. Unlike pentoxifylline, Cilostazol has been shown to increase both pain-free and maximal walking distances. Compared to surgical interventions, Cilostazol offers a non-invasive option with a favorable safety profile, though it may not be as immediately effective as revascularization procedures in severe cases.